Vaxcyte, Inc. — Director's Dealing 2021

Dec 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-12-09

Reporting Person: Fairman Jeff (VP, Research)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-09	Common Stock	M	131	$1.79	Acquired	6291	Direct
2021-12-09	Common Stock	S	131	$22.50	Disposed	6160	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-09	Stock Option (right to buy)	$1.79	M	131	Disposed	2027-05-17	Common Stock (131)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	341227	Indirect
Common Stock	50000	Indirect

Footnotes

F1: Includes 1,016 shares acquired under the Employee Stock Purchase Plan on November 17, 2021.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3: The shares subject to the option are fully vested and exercisable.